70 results about "Lung Inflammations" patented technology

The invention belongs to the technical field of biological medicines, and particularly relates to application of a nauclea officinalis extract in preparation of a medicine for treating chronic obstructive pulmonary diseases. Experimental research shows that the nauclea officinalis extract is used for treating the chronic obstructive pulmonary disease, can inhibit lung inflammation of a patient suffering from the chronic obstructive pulmonary disease and improve the lung function and emphysema injury of the chronic obstructive pulmonary disease, can be used for preventing and treating the chronic obstructive pulmonary disease, and can be used for preventing and treating the chronic obstructive pulmonary disease. And a new strategy is provided for the development of medicines for treating chronic obstructive pulmonary diseases.

The invention discloses application of a cytisine type alkaloid and a derivative thereof in preparation of a medicine for preventing or treating respiratory syncytial virus infection, and relates to the technical field of respiratory syncytial virus prevention and treatment. The research finds that the natural product cytisine shows good anti-respiratory syncytial virus infection activity in vivo and in vitro, and finds that the cytisine can obviously relieve lung injury caused by virus infection and reduce lung inflammation; the invention provides an experimental basis for developing an efficient and safe drug for resisting respiratory syncytial virus (RSV) infection. As a natural product, the cytisine reduces the social burden caused by treatment of respiratory syncytial virus infection and reduces the treatment cost.

The application discloses an FPR1 polypeptide blocker against lung inflammation and application thereof. The application provides a polypeptide shown in Sequence NO. 1, which can significantly improve lung tissue structure damage of a lung inflammation model mouse, reduce a proinflammatory factor level, reduce neutrophil infiltration, and show obvious anti-lung inflammation efficacy. Therefore, the polypeptide shown in Sequence NO. 1 has a prospect of development into an anti-lung inflammation drug.

This invention provides an application of the peptide Nod-T3 in the preparation of drugs for treating lung diseases. The Nod-T3 peptide is derived from human protein and has a significant inhibitory effect on chronic lung inflammation and fibrosis caused by smoking. It can be used to treat COPD and other smoking-related lung diseases. It also has high biocompatibility and low toxicity, and has the potential and development value to become a new type of peptide drug.

The invention discloses a preparation method and application of bioactive lipid and lipid nanoparticles thereof. The bioactive lipid molecule is formed by bonding long-chain fatty acid (LCFA) with different chain lengths with two functional small molecules, namely phenylboronic acid pinacol ester (PBAP) and Tempol (Tpl) respectively, so that two types of lipid molecules, namely PBAP-LCFA and Tpl-LCFA, with anti-inflammatory activity are constructed. The lipids are used as functional components, and the anti-inflammatory lipid nanoparticles with good biocompatibility, including PLP, TLP and TPLP, can be prepared through a film dispersion method. The lipidoid and the lipid nanoparticles are simple and convenient in preparation process, controllable in structure and function and easy for large-scale production, and have treatment potential in various acute and chronic inflammatory diseases. In an animal model, the lipid nanoparticles have remarkable curative effects on acute peritonitis, acute lung injury, acute hepatic failure, asthma and other diseases. Besides, the lipid bilayer structure of the TPLP can efficiently entrap hydrophilic / hydrophobic drugs, can synergistically deliver treatment drugs while exerting the anti-inflammatory effect of the TPLP, and realizes a synergistic combined treatment strategy for chronic lung inflammation and other diseases.

This invention discloses the application of 2,4-di-tert-butylphenol in the preparation of anti-human respiratory syncytial virus (RSV) drugs, belonging to the field of biomedical technology. 2,4-Di-tert-butylphenol exhibits good anti-RSV effects both in vitro and in vivo. In vitro, it can inhibit viral infection of cells, and in vivo, it can alleviate lung damage caused by viral infection and reduce lung inflammation. This invention provides experimental evidence for the development of highly effective and safe anti-RSV drugs and also offers more drug options for their development.

The application relates to kaempferol cerium nanoparticles and a preparation method and application thereof, and belongs to the technical field of biological medicines. The kaempferol cerium nanoparticles are prepared by performing coordination co-assembly on kaempferol and cerium ions in the presence of polyethylene glycol at a specific molar ratio, and the nanoparticles have uniform particle sizes and good dispersity. The nanoparticles have the anti-inflammatory activity of kaempferol and the ROS scavenging capacity of cerium ions, and show a significant synergistic effect in in-vivo and in-vitro experiments, can effectively reduce lung inflammation, inhibit oxidative stress, improve lung function, and have good biological safety, thereby providing a new drug candidate scheme for the treatment of ARDS.

This invention belongs to the field of biomedical technology, specifically relating to a rapid purification method for umbilical cord MSC exosomes and their application in the preparation of drugs for treating COPD. This invention discloses a method for rapidly purifying umbilical cord mesenchymal stromal cell (MSC) exosomes and a pharmaceutical composition comprising umbilical cord MSC exosomes and yamosaponin. In this pharmaceutical composition, the umbilical cord MSC exosomes and yamosaponin synergistically enhance the dynamic compliance of COPD rats, reduce airway resistance, decrease pulmonary inflammation, and repair pulmonary dysfunction. This invention provides a new technical solution for the preparation of drugs for treating or improving COPD.

The invention provides oral streptococcus ZRSOR-5 as well as a related product, a method and application thereof. The preservation number of the streptococcus oral cavity ZRSOR-5 provided by the invention in the Guangdong Microbial Culture Collection Center is GDMCC No: 65352, and the preservation number of the streptococcus oral cavity ZRSOR-5 provided by the invention is CGMCC No: 65352. Experiments prove that the SOR preparation is prepared by diluting the SOR preparation with normal saline and inhaling the SOR preparation into mice in advance, so that the survival rate of influenza virus infected mice can be remarkably increased, and lung inflammation and virus load can be reduced. When the ZRSOR-5 preparation provided by the invention is used in advance, pneumonia caused by influenza viruses can be resisted.

The invention discloses an application of glucopyranose galactooligosacharide in preparation of a medicine for treating and / or preventing allergic asthma. The invention finds that the glucopyranose galactooligosaccharide can obviously relieve airway inflammatory reaction of an allergen-induced allergic asthma model, including reducing airway inflammatory factor level, improving airway hyperreactivity and reducing lung inflammatory cell infiltration, and has no abnormal influence on blood routine and main organ functions; the composition has the advantages of small drug application dosage, low pharmaceutical cost, high safety, remarkable drug effect and the like, and has a wide application prospect.

A pharmaceutical composition for administering directly to the pulmonary tract of a subject includes a salt of triiodothyronine and a pharmaceutically acceptable buffer, adjusted to a pH of 5.5-8.5. The composition can be administered prophylactically or therapeutically to a subject to treat lung inflammation or pulmonary edema.

The invention relates to a system for measuring a level of a subject's immune activity (10), the system comprising: - an exhaled air sensor (20), - a device for measuring exhaled air (30), - computation means (40) suitable for determining data relating to the air exhaled by the subject from the measurements carried out by the device (30), - a memory (60) suitable for storing the measurements performed by the device (30) and / or the data calculated by the means (40), and the subject's personal data, - a computation means (70) suitable for determining a level of the subject's immune activity on the basis of at least one item of exhaled air data, generated in real time by the means (40) and / or stored in the memory (60), - a communication and management interface (80) suitable for presenting said level of the subject's immune activity and / or sub-scores of immunological activity, inflammatory activity, digestive inflammation and / or pulmonary inflammation.

To provide a pharmaceutical composition for treating lung inflammation in a mammalian subject having a granulomatous pulmonary disease.SOLUTION: A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a GHRH antagonist.SELECTED DRAWING: None

In some aspects, provided herein are compositions of and methods for utilizing a sterically stabilized liposome carrier encapsulating a selected drug for the delivery of such drug effectual in the treatment of a mammal infected by a virus, such as SARS-COV-2, specifically in inhibiting the viral replication and reducing symptoms including lung inflammation. The compositions and methods disclosed herein provide a potential treatment for COVID-19 with improved patient compliance as they offer a less frequent dosing for the “long haulers” post COVID-19 initial infection.

The invention provides a pollen vaccine based on an aluminum-CpG composite adjuvant and application of the pollen vaccine. The pollen vaccine comprises an aluminum-CpG chemical coupling nano adjuvant and a recombinant mugwort main allergen, the adjuvant is a substance formed by coupling an aluminum oxygen hydride nanorod and CpG through an amido bond, carboxyl on the surface of an AlOOH nanorod is activated, and then the AlOOH nanorod reacts with aminated CpG ODN to obtain the adjuvant. Stable combination of the aluminum salt nanoparticles and CpG ODN is achieved through chemical coupling, the coupling efficiency is larger than or equal to 95%, cytotoxicity is avoided, the problems that in traditional physical mixing, the aluminum salt nanoparticles and CpG ODN are not synergistic in effect and prone to dissociation are solved, and the synergistic immunoregulation effect of adjuvant components is ensured; after the adjuvant is loaded with the Artemisia pollen allergen Art v1, the IgE level can be remarkably reduced, lung inflammation can be relieved, allergic symptoms can be improved in treatment and prevention models, and a novel adjuvant platform is provided for immunotherapy of pollen allergy.

The invention provides a spanishneedles herb exosome as well as a preparation method and application thereof in acute lung injury, and belongs to the technical field of biological medicines. According to the preparation method of the spanishneedles herb exosome provided by the invention, the spanishneedles herb exosome can be extracted from a plant source through a simple method. In one embodiment of the invention, a lung injury model constructed by using LPS is used as an experimental animal to verify the therapeutic effect of the spanishneedles herb exosome. Results show that after the spanishneedles herb exosome is used for treatment, mouse lung tissue injury and inflammatory cell exudation can be relieved, and lung injury caused by LPS can be relieved; tNF-alpha and IL-1beta in lung lavage fluid of a mouse are remarkably reduced, and lung inflammation infiltration of the mouse can be relieved. Therefore, the spanishneedles herb exosome has the effect of treating the acute lung injury and can be used for preparing the medicine for treating the acute lung injury.

The invention relates to an application of Fgl2 gene knockout in antagonism of new coronavirus. In the technical scheme provided by the invention, a new crown infected mouse model is established through two SARS-CoV-2 mouse adaptive strains, namely, an MA17 strain and an MASCp36 strain, and it is verified that virus infection can promote Fgl2 expression up-regulation and fibrinogen deposition in mouse lung tissues; in addition, an SARS-CoV-2 mouse adaptive strain MA17 is utilized to infect an Fgl2 gene knockout mouse to prove that the Fgl2 gene knockout can antagonize lung inflammation infiltration, tissue damage, thromboembolism, fibrinogen deposition and fibrosis formation caused by virus infection, so that the occurrence of severe case and death of the mouse is reduced.

The invention provides a ganoderma lucidum molecular ecological liquid extract obtained through specific fermentation and a preparation method and application thereof, and belongs to the technical field of microbial fermentation. According to the method, an improved fermentation culture medium is adopted, 5-8% of CO2 is introduced, fermentation is performed for 90-180 days at the temperature of 30-32 DEG C under the condition that the concentration of dissolved oxygen in the environment is kept to be 20-30%, and after purification, the extract of the ganoderma lucidum molecular ecological liquid is obtained. According to the myxomycete molecular ecological liquid prepared by the preparation method provided by the invention, the content of active ingredients for relieving the symptoms of the chronic obstructive pulmonary disease can be remarkably increased; moreover, an in-vitro cell experiment verifies that the extract of the ganoderma lucidum molecular ecological liquid has an inhibition effect on an A549 cell line, and an animal experiment further proves that the extract of the ecological liquid can regulate and control the expression level of proinflammatory cytokines, so that lung inflammation is inhibited, pathological injury of lung tissues is relieved, and local abnormal conditions of the lung are improved.

The invention relates to the technical field of nano-drugs, in particular to a glucocorticoid nano-emulsion, a liposome, a freeze-drying preparation and application of the glucocorticoid nano-emulsion, the liposome and the freeze-drying preparation in treatment of acute lung injury. According to the glucocorticoid nano-emulsion and lipidosome, accumulation of a nano-preparation in an inflammation part can be effectively increased through SA modification, selective targeting of the nano-preparation on the inflammation part is achieved, acute lung inflammation of ALI mice is remarkably relieved through pulmonary drug delivery, and under the same dosage, compared with lipidosome, the dosage of the nano-emulsion and lipidosome is reduced, and the dosage of the nano-emulsion and lipidosome is reduced. The nano-emulsion shows the best anti-inflammatory treatment effect. The nano preparation provided by the invention is good in biological safety and has a wide development prospect.

Part of this invention provides novel small molecule PHD inhibitors having structures according to formula (I) and its derivatives: or pharmaceutically acceptable salts thereof. The compounds provided herein may be used to treat the following diseases: including heart diseases (e.g., ischemic heart disease, congestive heart failure, and valvular heart disease), lung diseases (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory diseases (e.g., respiratory infections, acute respiratory distress syndrome), liver diseases (e.g., acute liver failure, liver fibrosis, and cirrhosis), and kidney diseases (e.g., acute kidney injury and chronic kidney disease), inflammatory bowel disease (IBD), ischemic-reperfusion injury (e.g., stroke), and retinopathy of prematurity (ROP).

The invention discloses an andrographolide-based pH / ROS (Potential of Hydrogen / Reactive Oxygen Species) double-response double-drug loaded nano material as well as preparation and application thereof. The material is composed of an amphiphilic polymer (PEG-fan-shaped lysine-formyl phenylboronic acid) and hydrophobic drugs A and B, the drug A is covalently bound with the polymer through a borate bond to form a prodrug, and the drug B is physically wrapped in a nanoparticle hydrophobic core. The acidity and high reactive oxygen species (ROS) microenvironment of inflammatory lesions are utilized to trigger breakage of a Schiff base bond and a borate bond in a molecular chain, and the nanoparticles are induced to be disassembled and synergistically release double drugs. According to the invention, the enrichment degree and bioavailability of the drug at the lung inflammation part are obviously improved through passive targeting, efficient inhibition of inflammatory factor storm is realized, and a new scheme is provided for accurate delivery of hydrophobic anti-inflammatory drugs.

Disclosed herein are small anti-inflammatory peptides for blocking NF-κB. The peptides and compositions including the peptides can be administered to inhibit cytokine production and / or to inhibit lung inflammation in individuals in need thereof. Particular embodiments include administration to individuals suffering from coronavirus disease 2019 (COVID-19).

The application discloses a kind of based on CLDN1 protein's derivative peptide, fusion protein and its application, the derivative peptide includes the amino acid sequence as shown in SEQ ID NO:3, the amino acid sequence of the fusion protein is as shown in SEQ ID NO:2.The application finds that several derivative peptides containing CLDN1 protein extracellular loop EL1 peptide segment have significant inhibitory effect on various RNA and DNA envelope viruses.The fusion protein shows significant in vivo antiviral activity, can alleviate lung inflammation caused by RSV infection, and reduce viral nucleic acid level.Therefore, the derivative peptide and fusion protein based on CLDN1 protein designed in the application can be used for antiviral therapy or prophylactic drug research and development, and have wide application prospect.

To provide compositions and methods for the treatment of lung inflammation, including interstitial lung diseases (ILDs).SOLUTION: Embodiments of the present disclosure relate to therapies, including combination therapies for the treatment of lung inflammation, including interstitial lung diseases (ILDs), which include the use of at least one histidyl-tRNA synthetase (HRS) polypeptide or an expressible polynucleotide that encodes the HRS polypeptide, alone or in combination with at least one immunomodulatory agent. Embodiments of the present disclosure relate, in appropriate portions, to a therapeutic composition, comprising (a) an HRS polypeptide, or an expressible polynucleotide that encodes the HRS polypeptide and (b) an immunomodulatory agent.SELECTED DRAWING: Figure 3

The invention belongs to the technical field of biological medicines, and particularly discloses a polypeptide for protecting lung vascular endothelial cells and relieving lung injury and application of the polypeptide. The polypeptide is Humanin-G (HNG), and the amino acid sequence of the polypeptide is MAPRGFSCLLLLTGEIDLPVKRRA. The polypeptide is targeted to mitochondria of pulmonary vascular endothelial cells, provides protection from energy supply and cell survival roots, and has profound significance in improving functions of the pulmonary vascular endothelial cells and reducing the death rate of sepsis-induced acute lung injury (ALI). Researches show that when the polypeptide is used in the acute injury stage, lung inflammation of a model animal can be relieved by 25%-50%, the lung injury HE score can be reduced by about 50%, pulmonary edema can be relieved by about 30%, mitochondrial functions can be recovered by about 70%, the ATP yield can be increased by 30%, and the effect is excellent. Therefore, the invention provides a brand new strategy for maintaining the mitochondrial homeostasis by using the polypeptide so as to relieve lung injury.

A method for preparing inhalable targeted gold nanoparticles for accelerated lung delivery and treating lung inflammation is provided. The method includes preparing plasmids; performing plasmids transformation; performing protein expression induction; performing protein purification; and preparing spike RBD-conjugated gold nanoparticles (Au@PEG-RBD NPs). The airborne NP preferentially accumulates in lungs with lipopolysaccharides-induced ARDS to healthy lungs and enters alveolar epithelial cells that express angiotensin converting enzyme (ACE) 2 and L-SIGN, both Spike receptors activated in ARDS hamsters. The NP treats tissue injury, oxidative stress, and inflammation more effectively than corticosteroids, without gold retention in major organs or toxicity 1-year post-inhalation. The gold core blocks p38α mitogen-activated protein kinase and polo-like kinase 3. Similar efficacy is observed in hamsters with hydrochloric acid-induced ARDS. The self-therapeutic NPs, when combined with bioinspiration and non-invasive delivery, provide a safe, effective, and targeted treatment for lung inflammation.

The invention relates to application of a palmitoylation modification inhibitor in preparation of a medicine for treating or relieving allergic airway inflammation. The palmitoylation modified inhibitor is applied to the field of treatment of allergic airway inflammatory diseases for the first time. Experimental results show that the inhibitor can significantly inhibit activation of a JAK1 / STAT6 signal channel in vitro and effectively inhibit secretion of Th2 type inflammatory factors such as IL-4 and IL-13 by eosinophilic granulocytes; in animal model research, the palmitoylation modification inhibitor can obviously relieve allergic airway inflammatory reaction of mice, and the allergic airway inflammatory reaction is specifically shown as reduction of the number of eosinophils in bronchoalveolar lavage fluid (BALF), reduction of expression and secretion levels of BALF and lung tissue Th2 type inflammatory factors and obvious relieving of lung inflammation pathological degree. The invention provides a theoretical basis and a potential target for clinically developing a novel therapeutic drug for allergic airway inflammatory diseases in the future.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to application of radix polygonati officinalis addition and subtraction decoction in preparation of anti-Klebsiella products and in-vitro screening of anti-Klebsiella active ingredients. It is found for the first time that the addition and subtraction polygonatum odoratum decoction has remarkable bacteriostatic activity on Klebsiella, can remarkably lower the abundance of Klebsiella in intestinal tracts, can further remarkably inhibit formation of Klebsiella biofilms, promotes intestinal barrier repair, and relieves damage and inflammation of the intestinal tracts and lungs. Therefore, the polygonatum odoratum addition and subtraction decoction can be used for preparing products for resisting Klebsiella or preparing medicines for improving intestinal inflammation or lung inflammation.

The invention discloses application of inhibition of RUNX3 gene expression in preparation of medicines for preventing or treating silicosis, and belongs to the technical field of biological medicines. In-vivo and in-vitro silicosis models prove that the RUNX3 has high specificity expression in the silicosis process and is a key factor for driving disease progression. By inhibiting the expression of RUNX3 through a gene knock-down technology, silica-induced lung inflammation infiltration and collagenous fiber deposition can be significantly reduced, and the expression levels of key inflammatory factors (IL-1beta, IL-6 and TNF-alpha) and fibrosis indexes (Collagen I, Collagen III and Fibronectin) can be effectively down-regulated. Therefore, any substance capable of specifically inhibiting the expression of the RUNX3 gene, including but not limited to siRNA, shRNA, antisense oligonucleotide, ribozyme, microRNA and an inhibitor targeting the gene promoter thereof, can be used for developing the pharmaceutical composition for preventing or treating silicosis.

This invention belongs to the field of traditional Chinese medicine application technology and provides an application of a traditional Chinese medicine composition in the treatment of radiation-induced pneumonia. The traditional Chinese medicine composition is made from bamboo sap and *Trifolium repens*; the mass ratio of bamboo sap to *Trifolium repens* is (1-10):(1-10). Radiation-induced pneumonia refers to lung inflammation caused by radiotherapy for malignant tumors of the chest. The traditional Chinese medicine composition provided by this invention has the effects of clearing heat and detoxifying, resolving phlegm and dissipating nodules. It has a simple composition and high safety, providing a new option for the treatment of radiation-induced pneumonia.